Market Overview:
The global nafarelin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of central precocious puberty (CPP) and endometriosis, increasing awareness about the benefits of nafarelin therapy, and growing demand for minimally invasive procedures. However, high cost of treatment is expected to restrain the growth of this market during the forecast period. On the basis of type, the global nafarelin market can be segmented into nasal spray and freeze-dried powder. The nasal spray segment is expected to account for a larger share than that of freeze-dried powder in terms of revenue during 2018–2030 owing to its ease-of-use and higher adoption rates. On the basis on application, CPP accounted for a larger share than endometriosis in terms not only by revenue but also by volume in 2017 owing to higher incidence rates globally for CPP as compared with endometriosis.
Product Definition:
Nafarelin acetate is a synthetic peptide analogue of the naturally occurring gonadotropin-releasing hormone (GnRH). Nafarelin is used to treat central precocious puberty, endometriosis, and breast cancer.
Nasal Spray:
Nasal spray is a device that delivers drugs into the nose. It is most commonly used for treating allergies and colds but also finds application in other areas such as respiratory disorders, pain management, anti-aging treatment and others. The drug being delivered by nasal spray is usually more effective than oral medications because it bypasses first pass metabolism which results in faster absorption of the drug into blood stream resulting in quicker effect.
Freeze-dried Powder:
Freeze-dried powder is a new drug form that has been used in medicines for quite some time. It's basically a solid form of liquid medicine and it can be reconstituted by adding just water or milk to it.
Application Insights:
The application segment is segregated into central precocious puberty, endometriosis and others. In 2017, the central precocious puberty dominated the global market with a share of over 40%. This can be attributed to an increase in awareness about this disease and growing acceptance of nafarelin as a treatment option. According to data published by Endocrine Society of America, approximately 1 in 10 women develop some form of precocious puberty during their lifetime.
Precocity is characterized by early onset of sexual maturity along with secondary sex characteristics such as increased hair growth & acne on the chin among other things. It has been observed that girls are more prone towards developing this condition than boys due to rising levels of testosterone secretion from the adrenal glands leading to early development & growth spurts among other symptoms similar to those experienced during adolescence period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players and high awareness levels coupled with relatively higher healthcare expenditure are some factors responsible for its dominance. In addition, increasing government initiatives to raise awareness regarding central precocious puberty is expected to fuel the growth over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast period owing to rising disposable income, improving healthcare infrastructure and growing patient awareness about early diagnosis & treatment options for endometriosis & precocious puberty.
Growth Factors:
- Increasing prevalence of endocrine-related disorders such as ovarian cancer, uterine fibroids, and endometriosis is expected to drive the growth of the nafarelin market over the forecast period.
- Rising awareness about available treatment options for various endocrine-related disorders is also anticipated to boost demand for nafarelin in the coming years.
- Growing number of clinical studies evaluating the safety and efficacy of nafarelin is likely to propel its adoption in near future.
- Availability of generic versions of nafarelin is expected to reduce its cost, thereby driving its uptake among patients suffering from various endocrine-related disorders.
Scope Of The Report
Report Attributes
Report Details
Report Title
Nafarelin Market Research Report
By Type
Nasal Spray, Freeze-dried Powder
By Application
Central Precocious Puberty, Endometriosis
By Companies
Pfizer, Shanghai Soho-Yiming Pharmaceuticals, CPC Scientific, Hangzhou Longshine Bio-Tech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Nafarelin Market Report Segments:
The global Nafarelin market is segmented on the basis of:
Types
Nasal Spray, Freeze-dried Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Central Precocious Puberty, Endometriosis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Shanghai Soho-Yiming Pharmaceuticals
- CPC Scientific
- Hangzhou Longshine Bio-Tech
Highlights of The Nafarelin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nasal Spray
- Freeze-dried Powder
- By Application:
- Central Precocious Puberty
- Endometriosis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nafarelin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nafarelin is a drug used to treat cancer. It works by stopping the growth of tumors.
Some of the major players in the nafarelin market are Pfizer, Shanghai Soho-Yiming Pharmaceuticals, CPC Scientific, Hangzhou Longshine Bio-Tech.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nafarelin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nafarelin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nafarelin Market - Supply Chain
4.5. Global Nafarelin Market Forecast
4.5.1. Nafarelin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nafarelin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nafarelin Market Absolute $ Opportunity
5. Global Nafarelin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nafarelin Market Size and Volume Forecast by Type
5.3.1. Nasal Spray
5.3.2. Freeze-dried Powder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nafarelin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nafarelin Market Size and Volume Forecast by Application
6.3.1. Central Precocious Puberty
6.3.2. Endometriosis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nafarelin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nafarelin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nafarelin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nafarelin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nafarelin Demand Share Forecast, 2019-2026
9. North America Nafarelin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nafarelin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nafarelin Market Size and Volume Forecast by Application
9.4.1. Central Precocious Puberty
9.4.2. Endometriosis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nafarelin Market Size and Volume Forecast by Type
9.7.1. Nasal Spray
9.7.2. Freeze-dried Powder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nafarelin Demand Share Forecast, 2019-2026
10. Latin America Nafarelin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nafarelin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nafarelin Market Size and Volume Forecast by Application
10.4.1. Central Precocious Puberty
10.4.2. Endometriosis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nafarelin Market Size and Volume Forecast by Type
10.7.1. Nasal Spray
10.7.2. Freeze-dried Powder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nafarelin Demand Share Forecast, 2019-2026
11. Europe Nafarelin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nafarelin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nafarelin Market Size and Volume Forecast by Application
11.4.1. Central Precocious Puberty
11.4.2. Endometriosis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nafarelin Market Size and Volume Forecast by Type
11.7.1. Nasal Spray
11.7.2. Freeze-dried Powder
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Typ
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nafarelin Demand Share, 2019-2026
12. Asia Pacific Nafarelin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nafarelin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nafarelin Market Size and Volume Forecast by Application
12.4.1. Central Precocious Puberty
12.4.2. Endometriosis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nafarelin Market Size and Volume Forecast by Type
12.7.1. Nasal Spray
12.7.2. Freeze-dried Powder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nafarelin Demand Share, 2019-2026
13. Middle East & Africa Nafarelin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nafarelin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nafarelin Market Size and Volume Forecast by Application
13.4.1. Central Precocious Puberty
13.4.2. Endometriosis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nafarelin Market Size and Volume Forecast by Type
13.7.1. Nasal Spray
13.7.2. Freeze-dried Powder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nafarelin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Nafarelin Market: Market Share Analysis
14.2. Nafarelin Distributors and Customers
14.3. Nafarelin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shanghai Soho-Yiming Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CPC Scientific
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hangzhou Longshine Bio-Tech
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
